NR4A1 and breast carcinoma: These patients with triple-negative tumors have a relatively poor outcome and cannot be treated with endocrine therapy or therapies targeted to human epidermal growth factor receptor type 2 (HER2), in contrast with hormonal receptor positive and HER2+ breast cancers.